Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tcar-T
- Development stage
- Preclinical
- Lead developer
- Imgen BioSciences
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Tcar-T is a hybrid adoptive cellular immunotherapy platform being developed by Imgen BioSciences. The technology integrates T-cell receptor (TCR) and chimeric antigen receptor (CAR) approaches by utilizing TCR alpha/beta chains for antigen recognition, which are linked to a third-generation CAR activation signaling domain. This signaling domain incorporates CD28, 4-1BB (CD137), and CD3ζ costimulatory elements to enhance the activation, proliferation, and persistence of the engineered T cells. By combining the high-sensitivity antigen detection of TCRs with the potent, MHC-independent signaling of CARs, the therapy aims to address challenges in treating solid tumors and infectious diseases. The platform is currently in the preclinical stage of development.
- Other names
- TCR-CAR-THybrid TCR-CAR-T cell therapyT-cell receptor chimeric antigen receptor T-cell therapy
02
Targets
TNFSF9 (4-1BB ligand)
Beyond the preview
Go deeper on Tcar-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tcar-T.